Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) Short Interest Update

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) was the recipient of a significant increase in short interest in October. As of October 31st, there was short interest totalling 702,600 shares, an increase of 1,984.9% from the October 15th total of 33,700 shares. Based on an average daily trading volume, of 1,540,000 shares, the short-interest ratio is currently 0.5 days. Currently, 34.8% of the shares of the stock are sold short.

Shuttle Pharmaceuticals Stock Performance

Shares of NASDAQ:SHPH traded up $0.03 during midday trading on Tuesday, hitting $1.20. The company’s stock had a trading volume of 41,932 shares, compared to its average volume of 473,678. The business’s 50 day moving average is $1.42. The stock has a market cap of $3.54 million, a P/E ratio of -0.34 and a beta of -1.32. Shuttle Pharmaceuticals has a 12-month low of $1.03 and a 12-month high of $4.95.

Shuttle Pharmaceuticals (NASDAQ:SHPH) last posted its quarterly earnings results on Tuesday, September 3rd. The company reported ($0.96) earnings per share for the quarter.

Shuttle Pharmaceuticals Company Profile

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .